These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6257319)

  • 1. Neurotoxicity with desmethylmisonidazole.
    Dische S; Saunders MI; Stratford MR
    Br J Radiol; 1981 Feb; 54(638):156-7. PubMed ID: 6257319
    [No Abstract]   [Full Text] [Related]  

  • 2. The neurotoxicity of misonidazole: pooling of data from five centres.
    Disch S; Saunders MI; Anderson P; Urtasun RC; Karcher KH; Kogelnik HD; Bleehen N; Phillips TL; Wasserman TH
    Br J Radiol; 1978 Dec; 51(612):1023-4. PubMed ID: 216455
    [No Abstract]   [Full Text] [Related]  

  • 3. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.
    Wasserman TH; Phillips TL; Van Raalte G; Urtasun R; Partington J; Koziol D; Schwade JG; Gangji D; Strong JM
    Br J Radiol; 1980 Feb; 53(626):172-3. PubMed ID: 6245744
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma concentration of misonidazole and peripheral neuropathy.
    Marten TR
    Am J Clin Oncol; 1982 Apr; 5(2):239-40. PubMed ID: 6283876
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurotoxicity of Adriamycin and misonidazole in the mouse.
    Boegman RJ; Scarth B; Dragovic L; Robertson DM
    Exp Neurol; 1985 Jan; 87(1):1-8. PubMed ID: 2981696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misonidazole neuropathy.
    Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
    Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG; Makuch RW; Strong JM; Glatstein E
    Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic transformations in vitro produced by misonidazole.
    Miller RC; Hall EJ
    Cancer Clin Trials; 1980; 3(1):85-90. PubMed ID: 7389040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology.
    Coleman CN; Ballon SC; Howes AE; Martinez A; Halsey J; Hirst VK
    Gynecol Oncol; 1984 May; 18(1):18-27. PubMed ID: 6201419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurotoxicity of misonidazole: potential modifying role of dexamethasone.
    Workman P
    Br J Radiol; 1980 Jul; 53(631):736. PubMed ID: 7426903
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity.
    Jones DH; Bleehen NM; Workman P; Smith NC
    Br J Radiol; 1983 Nov; 56(671):865-70. PubMed ID: 6626878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
    Meering PG; Gonzalez DG; Maes RA; van Peperzeel HA
    Hum Toxicol; 1985 Jul; 4(4):425-34. PubMed ID: 4018823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misonidazole-a drug for trial in radiotherapy and oncology.
    Dische S; Saunders MI; Flockhart IR; Lee ME; Anderson P
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):851-60. PubMed ID: 227822
    [No Abstract]   [Full Text] [Related]  

  • 17. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.
    Wasserman TH; Phillips TL; Johnson RJ; Gomer CJ; Lawrence GA; Sadee W; Marques RA; Levin VA; VanRaalte G
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):775-86. PubMed ID: 227821
    [No Abstract]   [Full Text] [Related]  

  • 18. The neurotoxicity of radiosensitizing drugs: a biochemical assessment of desmethylmisonidazole (DMM) in the rat.
    Rose GP; Taylor JM
    Toxicology; 1985 Jan; 34(1):43-56. PubMed ID: 3918357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misonidazole also radiosensitizes some normal tissue.
    Arcangeli G; Nervi C; Mauro F
    Br J Radiol; 1980 Jan; 53(625):44-5. PubMed ID: 6766338
    [No Abstract]   [Full Text] [Related]  

  • 20. Loss of hearing after misonidazole.
    Abratt RP; Blackburn JD
    Br J Radiol; 1980 Dec; 53(636):1208. PubMed ID: 7437740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.